Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Holding LRMR?
Track your performance easily
LRMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.18 - $13.68
Previous Close$6.85
Volume1.05M
Average Volume (3M)523.52K
Market Cap
$437.08M
Enterprise Value$216.61M
Total Cash (Recent Filing)$226.06M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 12, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding63,806,628
10 Day Avg. Volume661,264
30 Day Avg. Volume523,520
Standard Deviation0.25
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.34
Forecast
1Y Price Target
$23.20Price Target Upside224.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Larimar Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase 2 placebo-controlled trial results announced showed that nomlabofusp increases the frataxin protein in adults with Friedreich's ataxia.
FDA SupportNomlabofusp was included in the FDA START pilot program, further underscoring unmet need in Friedreich's Ataxia.
Financial StabilityLarimar has $226M in cash, which the company believes is sufficient into 2026.
Bears Say
Clinical DataAnticipated higher levels of frataxin expression and more interpretable functional metrics were not observed in the initial data.
Operational DelaysThere was a lag in activating academic centers following the first patient being dosed in a non-academic center.
Regulatory RiskThere is an additional layer of risk since frataxin is not currently an accepted surrogate endpoint, and thus Larimar Therapeutics needs to produce evidence that frataxin levels can predict clinical benefit.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.18 and its highest was $13.68 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Aug 07, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.305 by -$0.035.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -$0.38.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 63,806,630 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.305. Following the earnings report the stock price went down -6.536%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Among the largest hedge funds holding Larimar Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Larimar Therapeutics, Inc.’s shares valued at 154M.
---
Larimar Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.20 (224.93% Upside)
$23.20 (224.93% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 304.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.26%
12-Months-Change
Fundamentals
Return on Equity
-37.48%
Trailing 12-Months
Asset Growth
112.29%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
---
LRMR Stock 12 Month Forecast
Average Price Target
$23.20
▲(224.93% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
TRACON Pharmaceuticals
―
Galera Therapeutics
―
Aclaris Therapeutics
―
Best Analysts Covering LRMR
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+34.30%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +34.30% per trade.
---